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REPERFUSION INJURY BY A NITRIC OXIDE DONOR 
Objective: One of the primary features of ischemia-reperfusion i jury is 
reduced production of protective autocoids, such as nitric oxide, by 
dysfunctional endothelium. Administration of a nitric oxide donor during 
reperfusion of lung grafts may therefore be beneficial through modulation 
of vascular tone and leukocyte and platelet function. Methods: Rat lung 
grafts were flushed with University of Wisconsin solution and reperfused 
for 1 hour in an ex vivo model incorporating a support animal. Group I 
grafts (n = 6) were reperfused immediately after explantation, group II 
(n = 6) and III (n = 5) grafts after 24 hours of storage at 4 ° C. In group III, 
glyceryl trinitrate, a nitric oxide donor, was administered uring the first 10 
minutes of reperfusion at a rate of 200 ptg/min. In an additional group (n = 
5), 200 pg/min hydralazine was administered instead, to assess the effect of 
vasodilation alone. Results: Graft function in group II deteriorated compared 
with that in group I, with significant reduction of graft effluent oxygen tension 
and blood flow and elevation of pulmonary artery pressure, peak airway 
pressure, and wet/dry weight ratio. In contrast, in group IH, glyceryl trinitrate 
treatment improved graft function to baseline levels in all these parameters. 
Administration of hydralazine, meanwhile, produced mixed results with only 
two out of five grafts functioning at control levels. Conclusions: In this model, 
administration of glyceryl trinitrate to supplement the nitric oxide pathway in 
the early phase of reperfusion has a sustained beneficial effect on lung graft 
function after 24-hour hypothermie storage, probably through mechanisms 
beyond vasodilation alone. (J Thorac Cardiovasc Surg 1997;113:327-34) 
T he susceptibility of lungs to ischemia continues to restrict storage times in clinical transplantation 
to about 6 hours. Even after such relatively short 
storage periods, graft dysfunction with increased 
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pulmonary vascular resistance, impaired gas ex- 
change, and pulmonary edema remains a significant 
cause of morbidity. This dysfunction may stem in 
part from ischemia-reperfusion njury. 
A key feature in the pathophysiologic process of 
ischemia-reperfusion injury is a fall in available 
levels of nitric oxide (NO) within minutes of the 
o set of reperfusion. TM NO has a number of regu- 
latory functions including vasodilation and inhibi- 
tion of platelet and leukocyte adhesion and activa- 
tion. 5 Increasing the availability of NO during 
reperfusion may therefore be beneficial to graft 
function. There is now considerable vidence to 
support this concept in the setting of myocardial 
ischemia-reperfusion. 6'7 Pulmonary endothelium, 
too, becomes dysfunctional after ischemia and 
reperfusion with impairment of NO-mediated re- 
sponses. 8 The addition of glyceryl trinitrate (GTN; 
also known as nitroglycerin), a NO donor, to flush 
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Fig. 1. Schematic representation f the reperfusion prep- 
aration. Deoxygenated blood from the inferior vena cava 
(IVC) of the support animal is hydrostatically delivered to 
the pulmonary artery of the graft, which is situated a 
vertical height (H) below. Graft effluent is returned to the 
right atrium (RA) of the support animal by a pump (P). V, 
Ventilator, T, pressure transducer, F, flowmeter. 
and storage solutions has recently been shown to 
enhance lung graft preservation in rodent mod- 
els. TM We hypothesized that administration of GTN 
during initial lung graft reperfusion, which is when 
the fall in NO levels is steepest, might attenuate 
progression of reperfusion injury. In a previous 
study we showed that protecting rat lung grafts for 
the first 10 minutes of reperfusion by reducing the 
reperfusion pressure to subphysiologic levels is ben- 
eficial to subsequent function. 12 Therefore GTN 
administration was limited to the initial 10 minutes 
of reperfusion on the basis that this might be 
sufficient to arrest development of reperfusion in- 
jury. 
Methods 
Isolated rat lung grafts were reperfused in a circuit 
incorporating a support animal. Male Sprague-Dawley 
rats (Charles River Laboratories, Kent, United Kingdom) 
weighing 350 to 420 gm were used and received humane 
care in compliance with the United Kingdom Govern- 
ment's Animals (Scientific Procedures) Act of 1986. All 
procedures were done with the use of terminal general 
anesthesia. Halothane inhalation and intraperitoneal pen- 
tobarbital sodium, 100 mg/kg, were used for anesthetic 
induction and maintenance, respectively. Animals' lungs 
and isolated grafts were ventilated with the use of Harvard 
rodent respirators (Harvard Apparatus, Kent, United 
Kingdom). 
Graft procurement. Anesthetized lung donors were 
intubated through a trache0stomy with a 16-gauge can- 
nula and the lungs ventilated with room air at 60 breaths/ 
min, 10 ml/kg tidal volume, and 3 cm H20 positive 
end-expiratory pressure. All donors were given methyl- 
prednisolone, 30 mg/kg, through the femoral vein 45 
minutes before lung explantation i  keeping with clinical 
practice. Median sternotomy was done, the pleurae and 
pericardium opened, and the thymus excised. A ligature 
was passed through the transverse sinus to encircle the 
aorta and pulmonary artery trunk. After heparinization 
(500 units), the inferior vena cava was clamped, the left 
atrial appendage amputated, and the right ventricular 
outflow tract opened. A primed, olive-tipped 20-gauge 
cannula was passed into the pulmonary artery trunk and 
secured with the previously placed ligature. The lungs 
were flushed through this cannula with a 60 ml/kg dose of 
4°C University of Wisconsin (UW) solution (DuPont 
Pharmaceuticals, Letchworth Garden City, United King- 
dom) delivered at 25 cm hydrostatic pressure. The tra- 
cheal cannula was then clamped with the lungs fully 
inflated and the heart-lung block was excised. 
Reperfusion. Support animals were anesthetized and 
the lungs ventilated as described for lung donors. Through 
a median sternotomy, mediastinal structures were ex- 
posed and the brachiocephalic artery ligated. A 16-gauge 
cannula was passed through the right superior vena cava 
and right atrium into the inferior vena cava. Deoxygen- 
ated blood drawn through this cannula was delivered 
hydrostatically into the pulmonary artery of the grafts, 
which were situated at a level below the support animal 
(Fig. 1). The vertical distance between the support ani- 
mals and grafts was designed to generate hydrostatic 
reperfusion pressure quivalent to the physiologic pulmo- 
nary artery pressure of these rats (18 to 20 mm Hg). The 
grafts, with the left lung and postcaval lobe removed, were 
suspended in an insulated chamber and ventilated with 
room air at 30 breaths/rain, 10 ml/kg tidal volume, and 3 
cm H20 positive end-expiratory pressure. Blood that 
drained from the opened left atrium of the grafts was 
collected and returned by a pump (Variable Speed Peri- 
staltic Pump, Harvard Apparatus) to the right atrium of 
the support animal through an 18-gauge cannula placed 
via the left superior vena cava. Thus the support animals 
continuously supplied deoxygenated blood to the grafts. 
The circuit tubing and reperfusion chamber were water- 
logged to maintain blood temperature at 38 ° C and sup- 
port animals were placed on a homeothermic warming 
blanket (Harvard Apparatus). Blood obtained from addi- 
tional animals was used to prime the circuit and to replace 
losses together with 0.9% saline solution. 
Experimental protocol. Grafts in group I (n = 6) were 
reperfused immediately after explantation to obtain base- 
line data. In groups II (n = 6) and Ill (n = 5), grafts were 
stored for 24 hours submerged in 40 C UW solution before 
reperfusion. All grafts were reperfused for a total of 60 
minutes. In group III, GTN was infused into the reperfu- 
sion circuit just proximal to the graft at a rate of 200 
t~g/min during the first 10 minutes of reperfusion. This 
dose was selected after pilot experiments in which lower 
doses had been found to yield partial improvement in 
function. 
Subsequently, an additional five grafts were reperfused 
after 24-hour storage in UW solution with administration 
of 200/~g/min hydralazine during the first 10 minutes of 
reperfusion. The objective was to establish whether the 
effects of GTN were mediated through vasodilation alone 
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Fig. 2. Partial pressure of oxygen (Po2) in graft effluent 
during 1 hour of reperfusion of grafts flushed with UW 
solution and reperfused immediately (group I) or after 
24-hour storage (groups II and III). Group III received 
200/zg/min GTN for the first 10 minutes of reperfusi0n. 
Data are shown as mean _+ standard error of the mean. 
**p < 0.001 versus group I. 
or through additional mechanisms. In pilot experiments, 
this dose of hydralazine produced the same (maximal) 
increase in blood flow in nonischemic grafts as 200/xg/min 
GTN with no adverse ffects on the support animal. 
Measurements. Graft effluent was sampled at 5, 10, 15, 
and 20 minutes and every 10 minutes thereafter for 
measurement of gas tension levels: Blood samples were 
also taken from the reperfusi0n circuit proximal to the 
graft at the same times for gas tension and acid/base 
measurements. This allowed monitoring of the stability of 
the condition of the support animal and the consistency of
(de)oxygenation f the reperfusate. An in-line ultrasonic 
flow probe (Transonic Systems, Ithaca, N.Y.) measured 
graft blood flow, and one lumen of the double-lumen 
reperfusion cannula was connected to a transducer for 
measurement of graft mean pulmonary artery (PA) pres- 
sure. Flow and PA pressure measurements were continu- 
ously digitalized and recorded onto a personal computer 
with the use of customized ata acquisition software 
(Dataq Instruments, Akron, Ohio). These data were later 
analyzed for point measurements at 2.5-minute intervals. 
The graft ventilator was linked to another transducer for 
measurement of peak airway pressure, which, with fixed- 
volume ventilation, reflects changes in compliance, Lung 
tissue was dissected free and weighed at the end of the 
reperfusion period and again after drying to a constant 
weight at 120 °C. Wet/dry weight ratio was calculated as 
(wet weight - dry weight)/dry weight. 
Statistical analysis. For groups I to IIL data are ex- 
pressed as mean -+ standard error of the mean, and means 
of values at the end of the 60-minute reperfusion period 
were compared by one-way analysis of variance. If differ- 
ences were found, the Bonferroni post hoc test was used 
for significance testing; p values less than 0.05 were 
considered significant. Data for grafts treated with hydral- 
azine were not distributed normally and are therefore 
presented individually. 
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Fig. 3. Graft blood flow during 1 hour of reperfusion of 
grafts flushed with UW solution and reperfused immedi- 
ately (group I) or after 24-hour storage (groups II and 
III). Group III received 200/xg/min GTN for the first 10 
minutes of reperfusion. Data are shown as mean plus or 
minus the standard error of the mean. **p < 0.001 versus 
group I. 
Results 
Reperfusion was maintained for 1 hour in all 
experiments with no deterioration of the stability of 
the support animal's condition as assessed by visual 
inspection of heart rate and cardiac filling, core 
temperature, and venous blood oxygen tension and 
pH values. Volume replacement requirements did 
not vary significantly among groups. The oxygen 
tension of the graft reperfusate was constant during 
individual experiments, as well as within and be- 
tween groups. This stability of the preparation has 
been documented in more detail in previous stud- 
ies. 13 
GTN administration. Oxygenation in grafts 
reperfused after 24-hour storage (group II) was 
poor compared with that in control ungs (Fig. 2); at 
1 hour, oxygen tension was 58 _+ 8 versus 131 _+ 2 
mm Hg (p < 0.001). In contrast, stored grafts that 
received GTN during the first 10 minutes of reper- 
fusion (group III) yielded oxygen tension values 
similar to those in group I (139 +- 4 mm Hg at 1 
hour, p = not significant). 
Deterioration of hemodynamic parameters oc- 
curred in group II with reduced blood flow (3.4 _+ 
1. 4 ml/min at 1 hour vs 10.6 _+ 0.5 ml/min in group 
I, p < 0.001) and elevated mean PA pressure 
(20.7 _+ 1.2 mm Hg vs 15.6 _+ 0.7 mm Hg, p < 0.01). 
In group III, during GTN administration, blood flow 
(Fig. 3) increased and PA pressure (Fig. 4) fell to 
group I levels. Both parameters subsequently stabi- 
lized at control levels and at 1 hour were 10.4 _+ 0.4 
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Fig. 4. Graft mean pulmonary artery pressure (MPA) 
during 1 hour of reperfnsion of grafts flushed with UW 
solution and reperfused immediately (group I) or after 
24-hour storage (groups II and III). Group III received 
200/xg/min GTN for the first 10 minutes of reperfusion. 
Data are shown as mean -+ standard error of the mean. 
*p < 0.0l versus group 1. 
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Fig. 5. Graft peak airway pressure (AWP) during 1 hour 
of reperfusion of grafts flushed with UW solution and 
reperfused immediately (group I) or after 24-hour storage 
(groups II and III). Group III received 200/~g/min GTN 
for the first 10 minutes of reperfusion. Data are shown as 
mean 4- standard error of the mean. *p < 0.01 versus 
group I. 
ml/min and 15.5 -+ 0.8 mm Hg, respectively (p = not 
significant vs group I). 
Peak airway pressure became levated in group II 
whereas in group III it remained similar to that in 
control ungs (Fig. 5). At 1 hour, values were 15 _+ 0 
mm Hg in group I, 32 _+ 5 mm Hg in group II (p < 
0.01 vs group I) and 15 _+ i mm Hg in group III (p = 
not significant). 
The wet/dry weight ratio in group II was elevated 
to 9.0 + 0.6 compared with 5.4 + 0.4 in group I (p < 
0.001), whereas in group III it was 7.1 -+ 0.7 (p = not 
significant). 
Hydralazine administration. Of the five stored 
grafts to which hydralazine was administered during 
the initial 10 minutes of reperfusion, two functioned 
at baseline levels, one was moderately impaired, and 
two performed poorly, with reduced oxygenation 
and blood flow and elevated PA and peak airway 
pressures (Fig. 6). The data are not presented as 
means or medians because of this distribution. 
Discussion 
This study has shown that isolated rat lung grafts 
reperfused after 24-hour storage in UW solution 
perform poorly in terms of oxygenation, blood flow, 
PA pressure, peak airway pressure, and weight gain, 
but that when GTN is administered during the first 
10 minutes of reperfusion, sustained improvement 
of function to baseline levels is achieved in all of 
these parameters. Further, this effect does not ap- 
pear to have been caused by vasodilation alone 
inasmuch as hydralazine did not afford protection as 
consistently. 
One of the physiologic functions of the endothe- 
lium is production of autocoids uch as prostacyclin, 
adenosine, and NO, which maintain local homeosta- 
sis by inhibiting vascular tone, platelet aggregation, 
and leukocyte activation and adhesion. A key fea- 
ture of the progression of ischemia-reperfusion n- 
jury is reduced endothelial production of these 
substances. 14 In models of myocardial ischemia- 
reperfusion, significant falls in NO-mediated, endo- 
thelium-dependent vasomotor esponses in artery 
segments have been demonstrated after only 2.5 
minutes 1 and 10 minutes = of reperfusion. Direct 
measurements have also shown a decline in myocar- 
dial NO levels early during reperfusion. 3 Pulmonary 
ischemia-reperfusion, too, produces endothelial dys- 
function. In a canine model of lung transplantation 
with the use of Euro-Collins solution for flush 
perfusion, relaxation of pulmonary artery rings de- 
pendent on endothelial production of NO was nor- 
mal after 3-hour hypothermic storage but was sig- 
nificantly impaired after 1 hour of reperfusion. 8 
Similarly, in pulmonary artery ring studies in a 
rabbit model, endothelium-dependent vasomotor 
responses were unaltered after up to 48 hours of 
cold storage in Ringer's lactate solution but were 
significantly reduced after 5 hours of storage and 4 
hours of reperfusion. 15 There may, however, be 
some species-related or flush solution-related vari- 
ation in these observations, because porcine lungs 
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flushed with low-potassium dextran solution exhib- 
ited impaired NO-dependent relaxations after flush- 
ing alone and after hypothermic storage without 
reperfusion. 16In studies in which direct measure- 
ments of NO were made in rat lungs with use of a 
porphyrinic microsensor, 6-hour storage in Ringer's 
lactate resulted in some reduction but after 10 
minutes of reperfusion levels of NO were consider- 
ably depressed. 4 Addition of superoxide dismutase 
resulted in restoration of NO levels, and the authors 
concluded that increased consumption of NO by 
reactive oxygen species may be more important than 
reduced production. 4 
NO has a wide spectrum of effects, 5loss of which 
may contribute to the development of ischemia- 
reperfusion i jury. It is a powerful vasodilator; this 
effect is mediated through increased levels of cyclic 
guanosine monophosphate (cGMP) in vascular 
smooth muscle cells. It inhibits platelet aggregation 
and adhesion to endothelium, again through stimu- 
lation of cGMP. 5 Adhesion of neutrophils to endo- 
thelium, which occurs after ischemia-reperfusion, s 
prevented by NO donors, z'17 This adherence is 
central to the activation and accumulation of neu- 
trophils in reperfused tissue in which they release 
destructive free radicals and enzymes. Increased 
endothelial permeability as assessed by albumin 
leakage from venules is inhibited by NO donors. 17 
NO also reduces availability of oxygen-derived free 
radicals by inhibiting production of superoxide by 
neutrophils s and directly scavenging reactive oxy- 
gen species. 19 
Considerable interest has therefore been directed 
toward strategies that supplement the NO/cGMP 
pathway in an effort to attenuate ischemia-reperfu- 
sion injury. Providing supplemental L-arginine, the 
substrate for endogenous production of NO, during 
myocardial ischemia-reperfusion ca improve myo- 
cardial performance and reduce endothelial dys- 
function, infarct size, and neutrophil accumula- 
tion.ZO, 21 Blocking production of NO with inhibitors 
of NO synthase, on the other hand, can be detri- 
mental to postischemic myocardial function. 21'22 
Solutions of NO, organic nitrates, and a number of 
other compounds that act as NO donors have been 
found to attenuate myocardial ischemia-reperfusion 
injury when administered during reperfusion (refer- 
ences 6 and 7 provide reviews). However, not all 
studies have found NO supplementation t  be ben- 
eficial; blocking NO synthesis can also reduce post- 
ischemic myocardial injury. 23' 24 It has been postu- 
lated that NO may contribute to such injury by 
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Fig. 6. Graft effluent Po 2 (A), blood flow (B), and mean 
pulmonary artery pressure (C) (MPA) during 1 hour of 
reperfusion of grafts tored for 24 hours in UW solution 
and receiving hydralazine, 200 tzg/min, for the first 10 
minutes of reperfusion. Data are for individual experi- 
ments. Grafts 4 and 5 performed at control levels. In graft 
3, oxygenation a d flow were moderately impaired, and 
grafts 1 and 2 functioned poorly. 
reacting with superoxide, with the production of 
peroxynitrite and hydroxyl radicals. 23' 24 
It is now becoming clear that the NO/cGMP 
pathway can also be beneficially modulated in pul- 
monary preservation. Addition of GTN to storage 
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solutions improved rat lung graft function and re- 
duced neutrophil and platelet accumulation after 
6-hour storage in Euro-Collins solution 9and 4-hour 
storage in Ringer's lactate. 1° In the same model, 
addition of a cGMP analog to the preservation 
solution also improved graft function. 4 We have 
previously demonstrated with our isolated rat lung 
reperfusion model that supplementation f Euro- 
Collins preservation solution with GTN yields sig- 
nificantly better graft function than supplementa- 
tion with prostacyclin. 11 Prostacyclin is also a 
vasodilator with antineutrophil and antiplatelet ac- 
tivity (mediated through cyclic adenosine mono- 
phosphate) and is widely used because of these 
properties in clinical lung transplantation. 
During lung reperfusion, it is possible to sup- 
plement NO levels by inhaled delivery of the gas. 
This produces vasodilation i  well-ventilated parts 
of the grafts, thus improving ventilation/perfusion 
matching, while rapid inactivation of NO by he- 
moglobin prevents systemic hypotension. How- 
ever, to date, mixed results have been achieved in 
attenuation of ischemia-reperfusion injury. In a 
rat lung transplantation model, inhaled NO treat- 
ment during reperfusion improved function in 
only 4 of 12 grafts whereas addition of a cGMP 
analog to the storage solution was uniformly 
beneficialY Injury in rat lungs undergoing 90 
minutes of warm in situ ischemia was significantly 
worsened when inhaled NO was administered 
from the onset of reperfusionY This effect was 
reversed by addition of superoxide dismutase or 
by delaying inhaled NO therapy for 10 minutes. 
The authors hypothesized that interaction of NO 
with the burst of superoxide that is generated at 
reperfusion, with production of toxic peroxynitrite 
and hydroxyl radicals, may be responsible for 
these observationsY 
In contrast, our current study has shown that 
administration of GTN during the first 10 minutes 
of reperfusion, which is when ischemia-reperfu- 
sion injury is triggered, has a sustained beneficial 
effect on lung graft function. GTN is an organic 
nitrate that is thought o exert its effects through 
liberation of NO intracellularly, as well as extra- 
cellularly, and also through production of S- 
nitrosothiol intermediates that directly stimulate 
cGMP production. 27 These mechanisms may be 
accompanied by generation of free NO in smaller 
quantities or in a different microenvironment 
compared with results with gas delivery by inha- 
lation, thereby limiting interaction with superox- 
ide. Another important factor may be that in our 
study grafts were ventilated with room air whereas 
in the inhaled NO studies, 70% 25 and 60% 26 
oxygen were used. Oxidant injury in ischemic- 
reperfused rat lungs has been shown to increase 
when high oxygen concentrations are used during 
reperfusion. 28Generation of reactive oxygen spe- 
cies and subsequent deleterious reaction with NO 
may therefore have been less marked in our 
model. 
In a previous study, we showed that if rat lung 
grafts were reperfused at physiologic pressure after 
24 hours of storage, marked deterioration of func- 
tion occurred, whereas if for the first 10 minutes 
reperfusion pressure was reduced by 50%, subse- 
quent function was similar to that in control ungs. 12 
In the current study, too, the protective ffect of 
intervention during the first 10 minutes was sus- 
tained subsequently throughout the period of reper- 
fusion, which underlines the critical importance of 
this initial phase of reperfusion. Although it is not 
possible from our results to identify which of the 
actions of GTN and NO discussed were responsible 
for the observed protection, vasodilation must play a 
major role in view of the partial benefit seen with 
hydralazine. 
Part of the vascular endothelial injury associated 
with lung graft preservation may derive from the 
flush/storage solution. There is concern that the 
high potassium concentration of the widely used 
Euro-Collins and UW solutions may be detrimental 
to endothelial function, and studies in which stan- 
dard UW solution has been compared with modified 
low-potassium UW solution have shown the latter to 
yield better graft function. 29 However, isolated ca- 
nine lobe studies have demonstrated that the in- 
crease in vascular tone caused by UW solution is 
slight and is less than that observed with Euro- 
Collins solution. 3° This may reflect the complex 
composition of UW solution, which includes the 
vasodilator adenosine. We elected to use UW solu- 
tion because it has repeatedly been shown to be 
superior to Euro-Collins solution for lung graft 
preservation i experimental studies and is increas- 
ingly being used in clinical lung transplantation. The 
mechanism of the effect of GTN administration i
our study may have included alteration of the endo- 
thelial response to exposure to UW solution. 
The dose of GTN used in this study was relatively 
high, and although the GTN did not adversely affect 
the support animal, it would probably cause unac- 
ceptable systemic hypotension if given to a trans- 
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plant  recipient.  However ,  the results highl ight the 
potent ia l  benef i ts  of supp lement ing  the NO/cGMP 
pathway dur ing lung graft reperfus ion,  and  further  
studies are warranted.  
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Discussion 
Dr. David A. Fullerton (Chicago, Ill.). Dr. Bhabra, I 
would like to congratulate you and your colleagues on a 
beautiful study. I wonder how many appreciate just how 
elegant he authors' model is. Any of us who are inter- 
ested in experimental studies dealing with lung transplan- 
tation have struggled with setting up a model. This really 
is a sophisticated yet simple and elegant model of lung 
transplantation. It offers the opportunity to study just 
about any aspect of the transplanted lung. I think that the 
authors have effectively demonstrated that by controlling 
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the initial reperfusate, one can clearly improve lung 
function. 
In this particular study, they elected to provide NO 
moiety through the reperfusion route, in other words, 
through the flow point of the ventilation-perfusion ratio. I
was curious if Dr. Bhabra might first discuss the pros and 
cons of offering inhaled NO as another oute of delivering 
the NO moiety. 
Dr. Bhabra. As you say, with lung grafts it is possible to 
deliver NO by inhalation. There have been a couple of 
papers published recently that both showed that inhaled 
NO was not beneficial. The reasons offered for this lack of 
benefit were that NO can react with superoxide and 
generate peroxynitrite and hydroxyl radicals, which can 
cause further injury. However, our model is amenable to 
all sorts of studies, and since the current study we have 
used low-dose inhaled NO and under specific onditions it
produces a similar benefit o that obtained with GTN. We 
have also done other studies in which we have been able 
to demonstrate hat the detrimental effect of NO can be 
overcome if you take certain precautions. 
Dr. Ful|erton. Although you used the hydralazine as a 
cohort o examine simply the vasoactive component of the 
nitroglycerin, I must say that I was impressed that three 
out of the five lungs demonstrated very good function 
after hydralazine administration, and I acknowledge that 
the authors appropriately analyzed the data in a different 
fashion. ! found it intriguing that three of those five lungs 
had near normal function, and so I was curious as to 
whether the authors have, for instance, had the opportu- 
nity to sample yon Willebrand's factor or to isolate the 
neutrophils that might be coming through this lung to 
study them in vitro to see whether they might behave 
differently in the various treatment groups. 
Dr. Bhabra. I believe that the vasodilation aspect is very 
important. We had a study published in the Annals of 
Thoracic Surgery this month in which we had found that 
simply by reducing the reperfusion pressure for the first 10 
minutes we obtained sustained benefits. I think that an 
important component of this finding is that during initial 
reperfusion there is an increase in endothelial permeabil- 
ity, and if the capillary or the PA pressure can be reduced, 
that in itself can be beneficial in preventing edema 
formation. In studies in which we have measured the 
endothelial permeability in the initial stage of reperfusion, 
we have found that permeability is quite high in the first 5 
minutes or so but then comes down. Hence if you protect 
the graft by either reducing reperfusion pressure or using 
dilators during this time, that in itself has a benefit. 
As for looking at other components, for example, 
neutrophils, we are working on that and are developing 
other assays too. 
Dr. Joseph Bavaria (Philadelphia, Pa.). We have done 
about 150 lung transplantations now clinically, and I think 
this is an interesting situation. The first question I have is, 
exactly when is the administration of nitroglycerin 
started? Are full dose and full levels achieved before 
opening up the reperfnsion of the lung? 
Dr. Bhabra. The way the model works is that the 
reperfusion limb of the circuit has to be clamped while we 
put the graft onto the circuit. Immediately before releas- 
ing the clamp, we started the GTN infusion, so there is not 
any preceding period of administration i to the circuit. 
Dr. Bavaria. Second, in clinical double-lung transplan- 
tation, in our bilateral sequential lung transplantation 
technique, the first lung is implanted, the clamps are taken 
off, and while both the native lung and the newly im- 
planted lung are being perfused there are reasonably 
good, that is, low, pulmonary artery pressures. Then, as 
soon as explantation of the second lung begins the first 
lung is relied on to do all the work, and the PA pressures 
generally rise by about 10 to 15 mm Hg for the 90 minutes 
or so that it takes to implant the second lung. Do the 
authors have any ideas for us that we might want to use 
during that period to help us with the reperfusion injury 
and the injury that occurs in the first implanted lung, 
which generally, even though it has a short ischemic time, 
generally has a worse appearance on the chest x-ray film 
afterward? 
Dr. Bhabra. I believe that this study is just setting out 
the concept hat if NO is supplied, the outcome can be 
improved, but I do not really believe that the doses of 
GTN that we were using in this study would be appropri- 
ate clinically, because they would almost certainly cause 
systemic hypotension. We have to look at other ways of 
delivering NO, and I do believe that inhaled NO is the 
future. It would be possible to use this in the first lung 
while procedures are being done in the second lung. 
